stella
beta
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients — Stella
Recruiting
Back to Metastatic HER2 Positive Gastroesophageal Junction Cancer trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang
View full record on ClinicalTrials.gov